hWJ-MSC Reduces IL-1β Gene Expression in Alzheimer's Rat Models

Objective: This study aims to study effect of Wharton's Jelly MSCs regulate IL-1β gene expression and to evaluate the potential of these MSCs as an innovative therapy for Alzheimer's disease; Method: This study was post test only control group design. Male Wistar rats were divided into three groups: Control, AlCl3, and AlCl3 + hWJ-MSC. AlCl3 (300 mg/kg/day) was administered orally for 5 days. hWJ-MSCs (1x106 cells) were injected intraperitoneally on day 11. Brain tissue RNA was isolated using TRIzol®, and cDNA synthesis was conducted. Gene expression was analyzed by real-time PCR; Result: The results of this study showed that the average of IL-1β levels in Negative Control, Positive Control and Treatment were 0.536 ± 0.342, 0.804 ± 0.801, 0.694± 0.303; Conclusion: Our study indicates that human Wharton's Jelly Mesenchymal Stem Cells (hWJ-MSCs) can reduce IL-1β levels in an Alzheimer's disease model, suggesting their potential to alleviate inflammation. Although the decrease was not statistically significant, these findings open new avenues for exploring hWJ-MSCs as a promising therapeutic option for Alzheimer's disease. Keywords: Alzheimer, hWJ-MSC, IL-1β, AlCl3